我院华法林临床应用分析 点击下载
论文标题: 我院华法林临床应用分析
英文标题:
中文摘要:

目的:了解我院住院患者华法林的应用情况,为规范其临床应用提供参考。方法:调取我院2013 年1 月-2014 年6 月应

用华法林的住院病历267 份,对华法林临床应用的适应证、用药剂量、国际标准化比值(INR)监测、出血并发症等进行系统的回顾

性调查分析。结果:我院华法林主要应用于深静脉血栓、脑梗死、风湿性心脏病及肺栓塞患者等;住院患者华法林用量范围为

0.625~6.875 mg,平均日剂量(2.15±0.72)mg;INR<1.8 的病例占52.8%,INR 在1.8~3.0(达标)的病例占31.8%,INR>3.0 的病

例占15.4%;华法林总不良反应发生率为5.6%,主要为皮下淤点(淤斑)和尿潜血,严重出血(脑出血)发生率为0.7%。结论:目前

华法林临床应用仍不够规范,INR达标率偏低,积极开展华法林用药干预和临床药学监护具有重要意义。

英文摘要:

OBJECTIVE:To investigate the clinical application of warfarin in inpatients of our hospital,and provide reference

for standardized application in clinic. METHODS:Totally 267 inpatients records used warfarin in our hospital from Jan. 2013 to

Jun. 2014 were investigated to retrospectively analyze the indications,dosage,international normalized ratio(INR)monitoring and

bleeding complications of warfarin. RESULTS:Warfarin was mainly used for patients with deep vein thrombosis,cerebral infarction,

rheumatic heart disease and pulmonary embolism in our hospital;the dosage of inpatients was in the range of 0.625-6.875 mg

with average daily dosage of(2.15 ± 0.72)mg;the INR lower than 1.8 accounted for 52.8% ,the INR in the range of 1.8-3.0

(reaching the standard)accounted for 31.8% and INR higher than 3.0 accounted for 15.4%;incidence of adverse reactions was

5.6% ,mainly subcutaneous blood spots (petechiae) and urine occult blood,and incidence of severe hemorrhage (intracerebral

hemorrhage)was 0.7%. CONCLUSIONS:At present,the clinical application of warfarin is still deficient,and qualified rate of

INR is still low. It’s important to actively carry out medication intervention and clinical pharmaceutical care.

期刊: 2016年第27卷第3期
作者: 徐丙发,林绪芳,孔薇,范鲁雁
英文作者: XU Bingfa,LIN Xufang,KONG Wei,FAN Luyan
关键字: 华法林;临床应用;国际标准化比值;调查分析;药学监护
KEYWORDS: Warfarin;Clinical application;International normalized ratio;Investigation and analysis;Pharmaceutical care
总下载数: 81次
本日下载数: 2次
本月下载数: 81次
文件大小: 619.60Kb

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!